Angel News

Angel News

Back to Homepage

14th September 2018

Archangels leads £1.3m fund raise for MGB Biopharma

A novel anti-bacterial agent which has been developed in Scotland by MGB Biopharma for the treatment of Clostridium difficile infections, is to enter Phase II clinical trials following a newly-completed £1.3m fund raise from existing and new investors, supplementing a £2.7m grant awarded earlier this year by Innovate UK.


Register now to read full story

In order to read the full story we need you to register with us, please click the link below:

Register Now

Add a comment:




Enter the characters in the image shown:

Back to Homepage